|
| |
Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods
|
Published: Jan 2012 | Pages: 87 | Pub ID: MM1326972367 |
|
|
|
 |
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Solid Organ Transplant Immunosuppressant Market to 2018 - Introduction
2.1 Overview
2.2 GBI Research Report Guidance
3 Solid Organ Transplant Immunosuppressant Market to 2018 - Market Overview
3.1 Introduction
3.1.1 Types of Transplant
3.1.2 Transplant Rejection
3.1.3 Immunosuppressive Drug Therapy
3.2 Market Forecast
3.2.1 Market Share by Disease Sector
3.2.2 Market Share by Geography
3.3 Annual Cost of Therapy
3.4 Target Population
3.5 Solid Organ Transplant Immunosuppressant Market Drivers and Restraints
3.5.1 Drivers
3.5.2 Restraints
4 Solid Organ Transplant Immunosuppressant Market to 2018 - Geographical Landscape
4.1 The US
4.1.1 Introduction
4.1.2 Revenue
4.1.3 Annual Cost of Therapy
4.1.4 Target Population
4.2 Top Five Countries of Europe
4.2.1 Introduction
4.2.2 Revenue
4.2.3 Annual Cost of Therapy
4.2.4 Target Population
4.3 Japan
4.3.1 Introduction
4.3.2 Revenue
4.3.3 Annual Cost of Therapy
4.3.4 Target Population
5 Solid Organ Transplant Immunosuppressant Market to 2018 - Therapeutic Landscape
5.1 Heart Transplant Market
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Therapy
5.1.4 Target Population
5.2 Lung Transplant Market
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Annual Cost of Therapy
5.2.4 Target Population
5.3 Kidney Transplant Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Target Population
5.4 Liver Transplant Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Target Population
5.5 Pancreas Transplant Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Target Population
6 Solid Organ Transplant Immunosuppressant Market to 2018 - Product Pipeline Analysis
6.1 Research and Development (R&D) Pipeline by Indication
6.2 R&D Pipeline by Phase
6.3 R&D Pipeline - Heart Transplant
6.3.1 Overview
6.3.2 Pre-Clinical Phase
6.3.3 Phase II
6.3.4 Phase III
6.4 R&D Pipeline - Lung Transplant
6.4.1 Overview
6.4.2 Pre-Clinical Phase
6.4.3 Phase II
6.4.4 Phase III
6.5 R&D Pipeline - Kidney Transplant
6.5.1 Overview
6.5.2 Pre-Clinical Phase
6.5.3 Phase I
6.5.4 Phase II
6.5.5 Phase III
6.6 R&D Pipeline - Liver Transplant
6.6.1 Overview
6.6.2 Pre-Clinical Phase
6.6.3 Phase II
6.6.4 Phase I
6.6.5 Pre-Clinical Phase
6.7 R&D Pipeline - Pancreas Transplant
6.7.1 Overview
6.7.2 Phase II
6.7.3 Phase III
7 Solid Organ Transplant Immunosuppressant Market to 2018 - Marketed Products
7.1 Prograf
7.1.1 Overview
7.1.2 Safety
7.1.3 Efficacy
7.2 Cellcept
7.2.1 Overview
7.2.2 Safety
7.2.3 Efficacy
7.3 Myfortic
7.3.1 Overview
7.3.2 Safety
7.3.3 Efficacy
7.4 Neoral
7.4.1 Overview
7.4.2 Safety
7.4.3 Efficacy
7.5 Zenapax
7.5.1 Overview
7.5.2 Safety
7.5.3 Efficacy
8 Solid Organ Transplant Immunosuppressant Market to 2018 - Competitive Landscape
8.1 F. Hoffman La Roche
8.1.1 Overview
8.1.2 Marketed Products
8.1.3 SWOT Analysis
8.2 Novartis AG
8.2.1 Overview
8.2.2 Marketed Products
8.2.3 SWOT Analysis
8.3 Genzyme Corporation
8.3.1 Overview
8.3.2 Marketed Products
8.3.3 SWOT Analysis
8.4 Astellas Pharma Inc.
8.4.1 Overview
8.4.2 Marketed Products
8.4.3 SWOT Analysis
9 Solid Organ Transplant Immunosuppressant Market to 2018 - Strategic Consolidations
9.1 Segmentation by Type
9.2 Segmentation by Year
9.3 Segmentation by Indication
9.4 Segmentation by Geography
9.5 Segmentation by Deal Value
9.6 Major M&As
9.7 Major Licensing Agreements
9.8 Major Co-Development Deals
10 Solid Organ Transplant Immunosuppressant Market to 2018 -Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Therapeutic Landscape
10.3.5 Market Size by Geography
10.3.6 Geographical Landscape
10.3.7 Pipeline Analysis
10.3.8 Competitive Landscape
10.3.9 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources |
|
| By: GBI Research |
|
|
| |
|
|
|
US Office
India Office